Clinical Trial

Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

Name: Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS) — clinical trial record (NCT07223983)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.

Protocol Amendment History 1 change

critical Recruitment opened 2026-05-13

Trial Details

NCT Number	NCT07223983
Lead Sponsor	Yale University
Conditions	Alcohol Use Disorder, Weight Loss, Bariatric Surgery Patients
Enrollment	10 participants
Start Date	2026-03-06
Primary Completion	2026-10-31 (estimated)
Study Completion	2026-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-12